212 related articles for article (PubMed ID: 32445449)
1. Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review.
Omidkhoda N; Vakilian F; Mohammadpour AH; Sathyapalan T; Sahebkar A
Curr Pharm Des; 2020; 26(31):3862-3870. PubMed ID: 32445449
[TBL] [Abstract][Full Text] [Related]
2. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study.
Maron BA; Opotowsky AR; Landzberg MJ; Loscalzo J; Waxman AB; Leopold JA
Eur J Heart Fail; 2013 Mar; 15(3):277-83. PubMed ID: 23111998
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptors in pulmonary hypertension and right heart failure: From molecular biology to therapeutic targeting.
Mamazhakypov A; Hein L; Lother A
Pharmacol Ther; 2022 Mar; 231():107987. PubMed ID: 34480966
[TBL] [Abstract][Full Text] [Related]
4. Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.
Bansal S; Badesch D; Bull T; Schrier RW
Contemp Clin Trials; 2009 Sep; 30(5):392-9. PubMed ID: 19375522
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.
Lu M; Chen LY; Gairhe S; Mazer AJ; Anderson SA; Nelson JNH; Noguchi A; Siddique MAH; Dougherty EJ; Zou Y; Johnston KA; Yu ZX; Wang H; Wang S; Sun J; Solomon SB; Vanderpool RR; Solomon MA; Danner RL; Elinoff JM
Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L315-L332. PubMed ID: 35043674
[TBL] [Abstract][Full Text] [Related]
6. The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.
Papademetriou V; Toumpourleka M; Imprialos KP; Alataki S; Manafis A; Stavropoulos K
Curr Pharm Des; 2018; 24(46):5517-5524. PubMed ID: 30806305
[TBL] [Abstract][Full Text] [Related]
7. Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure.
Ameri P; Bertero E; Meliota G; Cheli M; Canepa M; Brunelli C; Balbi M
Heart Fail Rev; 2016 Sep; 21(5):539-47. PubMed ID: 27206576
[TBL] [Abstract][Full Text] [Related]
8. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
[TBL] [Abstract][Full Text] [Related]
9. Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.
Fukuta H; Goto T; Wakami K; Kamiya T; Ohte N
Heart Vessels; 2019 Apr; 34(4):597-606. PubMed ID: 30315496
[TBL] [Abstract][Full Text] [Related]
10. Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure.
Rossi R; Crupi N; Coppi F; Monopoli D; Sgura F
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):119-25. PubMed ID: 23539659
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone antagonists in heart failure.
Miller SE; Alvarez RJ
J Cardiovasc Nurs; 2013; 28(6):E47-54. PubMed ID: 23001067
[TBL] [Abstract][Full Text] [Related]
12. The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series).
Maron BA; Leopold JA
Pulm Circ; 2014 Jun; 4(2):200-10. PubMed ID: 25006439
[TBL] [Abstract][Full Text] [Related]
13. The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure.
Pitt B
Heart Fail Rev; 2012 Sep; 17(4-5):573-9. PubMed ID: 21996778
[TBL] [Abstract][Full Text] [Related]
14. Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat.
Feldman RD; Sanjanwala R; Padwal R; Leung AA
Can J Cardiol; 2023 Dec; 39(12):1808-1815. PubMed ID: 37734710
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Young MJ; Funder JW
J Hypertens; 2002 Aug; 20(8):1465-8. PubMed ID: 12172301
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?
Kassem H; Chatila K
Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):258-263. PubMed ID: 31833939
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
18. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Hameedi A; Chadow HL
Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
Flatt DM; Brown MC; Mizeracki AM; King BJ; Weber KT
JAMA Cardiol; 2016 Aug; 1(5):607-12. PubMed ID: 27434136
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Adams KF
Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
